Francesca Barone - 26 Jan 2026 Form 4 Insider Report for Candel Therapeutics, Inc. (CADL)

Reporting relationship: Chief Scientific Officer
Issuer ticker: CADL
Reported as of: 26 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Jan 2026, 17:00:12 UTC
Prior SEC filing: 26 Jun 2025
Next SEC filing: 01 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Charles Schoch, as Attorney-in-Fact for Francesca Barone

Key filing fact

Francesca Barone filed Form 4 for Candel Therapeutics, Inc. (CADL) on 28 Jan 2026.

Key facts

This page summarizes Francesca Barone's Form 4 filing for Candel Therapeutics, Inc. (CADL).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 28 Jan 2026, 17:00.

Change

Previous filing in this sequence was filed on 26 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001909680 Primary reporting owner

Barone Francesca

Relationship: Chief Scientific Officer
Address: C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK ST., SUITE 450, NEEDHAM
Signature: /s/ Charles Schoch, as Attorney-in-Fact for Francesca Barone
Signature date: 28 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CADL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +232,000
Change %
Price: $0.000000
Shares after: 232,000
Date: 26 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 232,000
Exercise price: $6.01
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 26, 2026, subject to the Reporting Person's continued service on each vesting date.